RESUMO: "O papel controvertido da kava (Piper methysticum G. Foster) -Fitoterápico ansiolítico, na hepatite tóxica". Kava é um fi toterápico ansiolítico usado no tratamento da insônia e da ansiedade. Alguns casos de hepatotoxicidade induzida pela kava foram relatados na literatura, levando à proibição do seu uso em muitos países. Clinicamente, o espectro dessas alterações variou de elevações transitórias das enzimas hepáticas, até à falência hepática fulminante e morte. Em alguns casos, realizou-se transplante hepático. Este artigo revisa a literatura atual sobre a hepatite tóxica provavelmente relacionada à kava, discute os possíveis mecanismos responsáveis pela hepatotoxicidade potencialmente grave e descreve alguns aspectos que devem ser considerados quando eventos adversos hepáticos pareçam ser relacionados à administração dessa substância. Conclui-se que a possível toxicidade hepática pela kava ainda deve ser investigada e que algumas medidas antes e durante o seu uso são importantes, dada a possibilidade de disfunção hepática grave.
INTRODUCTION
Herbal medicines are being used by an increasing number of patients who typically do not advise their clinicians of their concomitant use. Natural products in folk medicine have been used for centuries (Cordeiro et al., 2005) , and they are generally regarded by the public as harmless remedies (Miller, 1998; Stickel et al., 2005) .
Nevertheless, hepatotoxicity could happen during some treatments with herbal remedies, and several of them have produced hepatitis in humans (Lekehal et al., 1996) . Therefore, potential hepatotoxicity of herbal products should not be underestimated (Dufour; StPierre, 2002) . When a patient presents with unexplained hepatic abnormalities, it may be worthwhile to consider non-orthodox self-treatment with herbal remedy as a potential cause (Pauwels et al., 1992) .
Kava or kava-kava (Piper methysticum G. Foster), an herbal product for sleep and anxiety disorders that contains kavalactones, is available over-the-counter in many countries (Russmann et al., 2001) . Recently, several reports about kava hepatotoxicity have been published, including fulminant liver failure, leading to liver transplantation (Kraft et al., 2001; Russmann et al., 2001; Gow et al., 2003; Humberston et al., 2003; Stickel et al., 2005) .
The concern over the possible hepatoxicity of kava has led several regulatory agencies in countries such as Germany, Switzerland, France, Canada, the United Kingdom, as well as the United States, warning consumers about the safety or potential risks of kava use, or removing kava-containing products from the marketplace (Food and Drug Administration, 2002; MCA, 2005; AFSSAPS, 2006) . The Brazilian regulatory agency Agência Nacional de Vigilância Sanitária (ANVISA) has determined (RE 356, February 28, 2002 ) that all products with kava must be registered and have a red label with the inscription "Dispensed with a medical prescription" (ANVISA, 2006) . This paper provides a review of the current literature on toxic hepatitis probably related to kava use and the questions about this herbal remedy. We reviewed data published between August 1966 and until June 2006 on databases MEDLINE / LILACS, PubMed (http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?DB=pubmed).
The search terms were "kava", "Piper methysticum", "hepatitis, toxic". We found 774 references and 65 of them were selected between full text articles, abstracts and correspondences in English, Portuguese, Spanish and French.
History, therapeutic use, pharmacology and side effects of kava (Piper methysticum)
Kava-kava (Piper methysticum) is a member of the pepper family (Piperaceae group) found in the South Pacifi c Islands, with medicinal use (Russmann et al., 2001) . The fi rst description of the plant was made by Swedish botanists during the fi rst expedition of Captain James Cook in the South Pacifi c area in 1768-1771 (Bilia et al., 2004) . This plant has been used for centuries as a highly revered ceremonial and medicinal drink producing mild narcotic effects (Yamada et al., 2003) . Folk medicine suggests that kava also may treat sleeplessness and tension/anxiety, headaches, colds, rheumatism, menopausal symptoms, venereal diseases, menstrual and genitourinary tract problems (Bilia et al., 2004) .
In the Western world, kava is commercially available as an herbal remedy and has been used predominantly to treat anxiety. Many studies suggest kava may be as effective as benzodiazepines (Andreatini et al., 2001; Bilia et al., 2002; Lehrl, 2004) . The signifi cant anxiolytic effect is assessed by the Hamilton Rating Scale for Anxiety, with good tolerability Ernst, 2000) . It is a well-established hypnotic drug, with a rapid onset of effect and adequate action period (Wheatley, 2005) .
Kavalactones (or kavapyrones) are considered to be the active constituents of kava-kava responsible for the pharmacological activity in humans and animals Ernst, 2000; Siméoni; Lebot, 2002; . There are 18 different kavalactones which are usually metabolized in the liver by the cytochrome P450 system (CYP450). The major are methysticin, dihydromethysticin, kavain, dihydrokavain, demethoxyyangonin, and yangonin, which account for 96% of the organic extract Levesque, 1989) . Dihydrokavain may be necessary and suffi cient in mediating the anxiolytic properties of P. methysticum extract (Feltenstein et al., 2003) .
There is also evidence for serotonergic and calcium antagonistic potencies of kavain, but the cellular actions of this kavapyrone appear heterogeneous, all of them counter excitation (Grunze; Walder, 1999) . Sleep disturbances associated with non-psychotic anxiety disorders can be effectively and safely treated with kava extract (Lehrl, 2004) , nevertheless authors suggests that it might prove to be a useful treatment for epilepsies, bipolar disorders, depression and anxiety, all conditions characterized by increased cellular excitability (Grunze; Walder, 1999) . Methysticin and kavain inhibit voltageoperated sodium channels in rat neurons (Magura et al., 1997) .
The mechanisms to explain the anxiolytic action of kava probably involve a reduction in the excitability of the limbic system, particularly the amygdala complex.
Pharmacological properties of Piper methysticum include blockade of voltage-gated sodium ion channel; enhanced ligand binding to gamma-aminobutyric acid (GABA) type A receptors (kavapyrones are GABA receptors agonists through the inhibition of activating neurons in the reticular formation and the limbic system); diminished excitatory neurotransmitter release due to calcium ion channel blockade; reduced neuronal reuptake of noradrenaline; reversible inhibition of monoamine oxidase B and suppression of the synthesis of the eicosanoid thromboxane A2, an antagonist of GABA A receptor function (Clouatre, 2004) . Although it is suggested that kava should be a dopamine antagonist, available data are not conclusive (Stevinson, 2002) .
Before 1998, extracts of kava were considered to be very safe alternatives to anxiolytic drugs (Clouatre, 2004) . Adverse effects imputed to kava were generally considered to be mild or negligible. It may cause dermatological side-effects (Ernst, 2000) ; oral (Abebe, 2002) and neurological manifestations (Spinella, 2001; Meseguer et al., 2002; Sibon, 2002) . Myoglobinuria has also been reported after ingestion of an herbal combination product containing kava (Donadio et al., 2000) .
However, in the past few years, severe side effects, including liver damage resulting in a few cases of mortality, have been reported. Nowadays, a total of 78 cases of hepatotoxicity reputedly linked to kava ingestion are available from various databases (Clouatre, 2004; Côté et al., 2004) .
Toxic hepatitis induced by kava
Kava use is associated with liver damage and the potentially severe hepatotoxicity of kava is emphasized by Stickel et al. (2003) . Using a clinical diagnostic scale established for adverse hepatic drug reactions, they analyzed 29 cases of hepatitis along with kava ingestion which occurred between 1990 and 2002, in addition to the seven already published case reports suggesting the development of hepatitis after the intake of kava. Lack of dose-dependence of kava-associated adverse hepatic events was evident in this report.
Nine patients developed fulminant liver failure, of which eight patients underwent liver transplantation. Three patients died, two following unsuccessful liver transplantation. In all other patients, a complete recovery was noticed after the withdrawal of kava. Hepatic necrosis or cholestatic hepatitis was noticed with both alcoholic and acetonic kava extracts.
Liver biopsy showed infi ltrated portal tracts, bridging necroses, destruction of interlobular bile ducts, and canalicular cholestasis. A mixed cellular infi ltrate (lymphocytes, eosinophil granulocytes and activated macrophages) involving interlobular bile ducts was a histopathologic fi nding (Russman et al., 2001) . Marked eosinophilic infi ltrated is showed in some cases (Stickel et al., 2003) .
Recently, Musch et al. (2006) reported an acute hepatitis in a previous healthy 48-year-old female, with histological characteristics of a toxic origin, classifi ed as induced immunologic idiosyncratic hepatitis. She was taking simultaneously kava and St John's Wort, an inducer of CYP450 3A enzymes, which possibly potentiated the toxicity of kavapyrones.
Kava has hepatotoxic effects (De Smet, 2002) , but the precise mechanism or mechanisms through which kava might induce liver damage is unknown. Whether kava is more hepatotoxic than conventional anxiolytic drugs is also unclear (Ernst, 2002) .
Drugs are metabolized by a variety of processes involving oxidation, reduction and hidrolysis (phase I reactions) or glucuronidation, sulfation, acetylation, and methylation (phase II reactions) (Wilkinson, 2005) . The pathogenesis of drug or toxin-induced liver injury usually involves the participation of toxic metabolites that either elicit an immune response or directly affect the biochemistry of the cell (Kaplowitz, 2002) .
The best understood example of this process is acetaminophen intoxication. Safe in recommended therapeutic doses, large amounts of acetaminophen cause cellular necrosis, caused by a highly reactive metabolic product, N-acetiyl-benzoquinone-imide (NAPQI) (Maddrey, 2005) . Cell death is the crucial event leading to the clinical manifestations of druginduced hepatotoxicity and the liver is usually the target of the immune system, but some drugs produce metabolites that also cause cell death independent of the extrinsic immune system (Kaplowitz, 2002) . Pathophysiologically, both immunoallergic and idiosyncratic factors may be responsible. It is suggested that, in many cases, an individual metabolic idiosyncrasy must be considered (Stickel et al., 2005) .
On the other hand, differences in drug response among patients are common. In druginduced hepatotoxicity, it is likely that the individual risk is determined by various combinations of the environmental and genetic variations in multiple factors (Kaplowitz, 2002) . Genetic predisposition may be a risk factor for developing kava-related liver disease. In fact, toxic hepatitis in poor-metabolizer phenotype of cytochrome P450 2D6 are reported by Russmann et al. (2001) .
Possible mechanisms for kavalactones hepatotoxicity
Whether kava or its constituents are hepatotoxic, where does liver toxicity come from? Three possible mechanisms for kavalactones hepatotoxicity are known: inhibition of cytochrome P450 (CYP 450), reduction in liver glutathione (GSH) content and, more remotely, inhibition of cyclooxygenase enzyme (COX) activity (Johnson et al., 2003; Whitton et al., 2003; Clouatre, 2004) .
Drug interactions can raise the possibility of adverse effects (Wilkinson, 2005) . Interactions between herbal and conventional drugs undoubtedly do occur and may put individuals at risk to develop adverse reactions (Fugh-Berman; Ernst, 2001; Côté et al., 2004) . Many of these drug interactions are a result of inhibition or induction of cytochrome P450 enzymes, which are responsible for the metabolism of many drugs (Wilkinson, 2005) . Kava has great potential for adverse effects, due the inhibition of several of these enzymes, resulting in pharmacokinetic interaction (Mathews et al., 2002) .
In fact, whole kava extract decreases activities of CYP1A2, 2C9, 2C19, 2D6, 3A4 and 4A9/11 in human liver microsomes. Kavain did not inhibit these enzymes, but desmethoxyyangonin, methysticin and dihydromethysticin inhibit CYP2C9; dihydromethysticin inhibit CYP2C19; methysticin inhibit CYP2D6; desmethoxyyangonin, methysticin and dihydromethysticin inhibit CYP3A4 (Mathews et al., 2002) .
Certain individuals might be especially susceptible to kava-induced hepatotoxicity. A possible mechanism of kava-induced hepatotoxicity is suggested for cases in which the detoxifi cation pathways for kavapyrones metabolites are modifi ed. The formation of electrophilic quinoid metabolites (quinones) by hepatic microsomes in vitro suggests that they might contribute to liver injury, when the detoxifi cation pathways become altered by a drug interaction, by a genetic difference in enzyme expression or if conjugation pathways become saturated (Johnson et al., 2003) .
Controversies about kava-related toxic hepatitis
Despite these several theories as to the mechanism of kava hepatotoxicity, there is still no satisfactory answer. Some authors consider that on closer inspection, the majority of the case reports are probably not connected to kava intake (Denham et al., 2002; Anke; Ramzan, 2004) .
The current discussion of potential deleterious effects of kava on liver calls for a closer look at the available data of the observed adverse effects connected to its intake.
Attribution of liver injury to a specifi c drug in a patient may be diffi cult, because the manifestations are sometimes similar to acute viral hepatitis (nausea, vomiting, jaundice, increased aminotransferases levels). There is no gold standard for the diagnosis in druginduced liver disease but clinical scales for causality assessment may be applied, facilitating the interpretation of fi ndings (Naranjo at al., 1981; Kaplowitz, 2001 ). However, its true incidence is diffi cult to determine, and it is sometimes underestimated Navarro; Senior, 2006) . Therefore, extensive research for others causes of liver disease must be performed (Teschke et al., 2003) .
In the spectrum of hepatic manifestations of drug-induced liver disease, the most frequent is acute hepatitis, with hepatocellular necrosis or cholestasis (or mixed hepatitis), ranging from minimal or moderate biochemical alterations to acute liver failure and death; chronic manifestations are less common (Maddrey, 2003) . Eventually, AST and ALT levels could reach 30 times higher the upper normal limit, without symptoms or signs, in previously healthy patients (Amorim et al., 2005) . Toxic effects of intentional overdose of acetaminophen may show extremely high aminotransferase levels (Lee, 2003) .
There is no evidence for serious liver damage in kava-using populations in Pacifi c Island societies or in Indigenous Australians who have used moderate levels of consumption of aqueous kava extracts. Changes in liver function tests as high levels of liver enzymes gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) appear to be reversible after 1 to 2 weeks abstinence from kava (Clough et al., 2003) . Russmann et al. (2003) also consider that the increased activity of GGT in heavy kava consumers in New Caledonia, in the presence of normal or minimally elevated transaminases is probably not a sign of liver injury, but rather refl ects an induction of CYP450 enzymes.
In a background data on a total of 76 case reports of kava hepatotoxicity dating from 1990 to 2002, Schmidt (2006) suggested a possible or probable connection to kava in only one case, and considered that the risk of adverse liver effects seems to be very low. In rats, aqueous kava extracts do not affect liver function tests, nor malondialdehyde formation, which refl ects the lipid peroxidation (Singh; Devkota, 2003) .
DISCUSSION
Kava is cited among liver injury inducing drugs (Stickel et al., 2003) , with predominantly hepatocellular pattern (Navarro; Senior, 2006) . Even authors who consider hepatotoxicity in the course of kava use a rare adverse event, suggest safety recommendations and recognize the possibility of hepatotoxic effects (Teschke, 2003) .
Kava has been shown to cause a decrease of glutathione in the liver (Clouatre, 2004) . Hepatic GSH defi ciency can disturb the physiological balance between apoptosis and necrosis, infl ammation and proliferation and predisposes cells to oxidative injury. Liver toxicity of xenobiotics is greatly enhanced under this condition (Hentze et al., 2000) . Glutathione plays an essential role in the phase II conversion of lactones into excretable waste products. Consequently, on glutathione depletion, increased side effects may occur (Whitton et al., 2003) . Intracellular glutathione depletion by chronic and excessive ingestion of alcohol may also results in acetaminophen poisoning (Maddrey, 2005) .
Kavalactones inhibit cyclooxygenase enzymes (COX-1 and COX-2) and this inhibition has been linked in other therapeutic drugs to hepatotoxicity, which is a common fi nding with drugs with this property and contribute to the risk of drug-induced liver disease (Clouatre, 2004) .
Interactions between other drugs and herbal remedies is a very important question (Blendis, 2005) , because kava is often consumed in combination with other pharmaceuticals metabolized by CYP3A4. In several cases reports, other medications with hepatotoxic potencial were being taken concurrently with kava by the patients (Stevinson, 2002; Cordeiro et al., 2005) , raising the risk of toxic hepatitis.
The different methods of extraction of kavalactones from the roots may explain the toxicity of Western products compared with the safe use of the traditional beverage (Whitton et al., 2003) . Once there are disparities between caplets and kava root extracts prepared using methanol, ethanol or acetone, the differences in the ratio of the kavalactones imply possible variations in biological activity and the hepatotoxicity could be the result of CYP450 inhibition, more pronounced for commercial preparations (Côté et al., 2004) .
Herbal preparations are frequently contaminated with heavy metals, micro-organisms, toxic substances and adulterated with synthetic drugs (Bogusz et al., 2002) . Alkaloid contamination may play a key role in the liver toxicity associated with kava. Tests in vitro with exposure of human hepatoma cells (HepG2), to pipermethystine (a major kava alkaloid), suggest that it is, rather than kavalactones, capable of causing cell death, probably in part by disrupting mitochondrial function. Pipermethystine signifi cantly decreased cellular ATP levels, mitochondrial membrane potential, and induced apoptosis as measured by the release of caspase-3 after 24 h of treatment (Nerurkar et al., 2004) .
Interaction between kava and ethanol is possible, and has important clinical consequences, such as the increased central nervous system depression. Whether this combination leads to liver damage are confl icting fi nds. In mice, ethanol increases the toxicity of kava, and in a community in Australia, non heavy alcohol users showed GGT and ALP levels higher than nonusers (Clough et al., 2003) .
Authors suggest avoiding the concomitant use of alcohol and kava extracts, due to the changes in hepatic elimination of drugs that occur in alcohol addicts (Stevinson, 2002; Schmidt, 2006) .
Although some investigators support that it is highly suggestive that kava itself produces toxicity, all these features described above must be considered because they are important to understanding what is going on with the patient taking kava, when liver disease appears.
CONCLUSION
Based on data found in the literature, we conclude that the incidence of kava toxicity on the liver remains to be investigated. In countries where kava products are available, clinicians, practicing physicians and clinical pharmacists must be aware of the toxic potential of this herbal sedative.
They should ask all patients about this use and always inquire about their intake in cases of unexplained liver injury. Previous hepatic impairment should be considered a contraindication for prescription.
Drug interactions can raise the possibility of adverse effects and drug metabolism may vary markedly among patients. Therefore, special care must be taken in cases of concomitant administration and these patients should be routinely and individually monitored.
Because of the possibility of kava-induced hepatotoxicity, a work-up for alternative causes of liver disease occurring during kava use is needed. Multiple factors may contribute to hepatic failure, which could become a life-threatening condition, even fatal.
